CN1726031A - 8－三烷基硅氧基－2－甲基－9－苯基－7－氧代－7,8,9,10－四氢咪唑并[1,2－h][1,7]二氮杂萘 - Google Patents
8－三烷基硅氧基－2－甲基－9－苯基－7－氧代－7,8,9,10－四氢咪唑并[1,2－h][1,7]二氮杂萘 Download PDFInfo
- Publication number
- CN1726031A CN1726031A CNA200380105889XA CN200380105889A CN1726031A CN 1726031 A CN1726031 A CN 1726031A CN A200380105889X A CNA200380105889X A CN A200380105889XA CN 200380105889 A CN200380105889 A CN 200380105889A CN 1726031 A CN1726031 A CN 1726031A
- Authority
- CN
- China
- Prior art keywords
- formula
- alkyl
- methyl
- hydrogen
- chemical compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000005054 naphthyridines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 40
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 26
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 15
- 239000001257 hydrogen Substances 0.000 claims abstract description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 15
- 150000003839 salts Chemical class 0.000 claims abstract description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 150000002431 hydrogen Chemical group 0.000 claims abstract description 5
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 29
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 4
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 150000002466 imines Chemical class 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract description 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 abstract 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 abstract 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 abstract 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 235000002639 sodium chloride Nutrition 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 4
- -1 heptyl (5-methyl hexyl) Chemical group 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- SWHFSXDXCWCNKQ-UHFFFAOYSA-N ethyl 3-anilino-2-hydroxypropanoate Chemical compound CCOC(=O)C(O)CNC1=CC=CC=C1 SWHFSXDXCWCNKQ-UHFFFAOYSA-N 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- MXBVNILGVJVVMH-UHFFFAOYSA-N 1,7-naphthyridine Chemical compound C1=NC=CC2=CC=CN=C21 MXBVNILGVJVVMH-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- OVEHNNQXLPJPPL-UHFFFAOYSA-N lithium;n-propan-2-ylpropan-2-amine Chemical compound [Li].CC(C)NC(C)C OVEHNNQXLPJPPL-UHFFFAOYSA-N 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- UWMJRBYGKZOPCC-UHFFFAOYSA-N 1-chloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)NC1=O UWMJRBYGKZOPCC-UHFFFAOYSA-N 0.000 description 1
- AQZMINLSVARCSL-UHFFFAOYSA-N 4-chloro-3,6-dioxocyclohexa-1,4-diene-1,2-dicarbonitrile Chemical compound ClC1=CC(=O)C(C#N)=C(C#N)C1=O AQZMINLSVARCSL-UHFFFAOYSA-N 0.000 description 1
- DCERHCFNWRGHLK-UHFFFAOYSA-N C[Si](C)C Chemical compound C[Si](C)C DCERHCFNWRGHLK-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- RISRGKINPSVAJP-UHFFFAOYSA-N [Li].C(CCC)(=O)O Chemical compound [Li].C(CCC)(=O)O RISRGKINPSVAJP-UHFFFAOYSA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 150000005232 imidazopyridines Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical class O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- RWMKSKOZLCXHOK-UHFFFAOYSA-M potassium;butanoate Chemical compound [K+].CCCC([O-])=O RWMKSKOZLCXHOK-UHFFFAOYSA-M 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 150000007984 tetrahydrofuranes Chemical class 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
8－三烷基硅氧基－2－甲基－9－苯基－7－氧代－7，8，9，10－四氢咪唑并[1，2－h][1，7]二氮杂萘，式(1)化合物及其盐是制备预防和治疗肠胃病的化合物的有用的中间体。其中R1是氢，甲基或羟甲基，R2a和R2b都是氢或一起表示一个键，R3是1－7C烷基，R4是1－7C烷基，和R5是1－7C烷基。
Description
发明领域
本发明涉及新的化合物，其作为制备药物的中间体应用于制药工业。
现有技术
国际专利申请WO 02/34749、WO 01/72757、WO 01/72756、WO01/72754、WO 00/17200和WO 98/42707公开了具有特殊取代模式的三环咪唑并吡啶衍生物，其适用于治疗胃肠疾病。在该专利申请中，给出了反应示意流程，其中表明从咪唑并吡啶-8-酮开始制得了最终产品。这些咪唑并吡啶-8-酮更详细地描述在国际专利申请WO 01/72748中。
发明内容
本发明涉及一类化合物，其可用作制备现有技术中提及的化合物的重要的中间体；还涉及具有类似基本结构的其他化合物。
因此，第一方面，本发明涉及式1化合物及其盐，
其中，R1是氢、甲基或羟甲基，
R2a和R2b都是氢或一起表示一个键，
R3是1-7C烷基，
R4是1-7C烷基，和
R5是1-7C烷基。
1-7C烷基表示具有1-7个碳原子的直链或支链烷基。可提及的实例有庚基，异庚基(5-甲基己基)，己基，异己基(4-甲基戊基)，新己基(3，3-二甲基丁基)，戊基，异戊基(3-甲基丁基)，新戊基(2，2-二甲基丙基)，丁基，异丁基，仲丁基，叔丁基，丙基，异丙基，乙基和甲基。
式1化合物的适宜的盐具体是与强碱形成的所有的盐，例如钠、钾或锂盐。
所要强调的式1化合物为这样一些化合物及其盐，其中
R1是甲基，
R2a和R2b都是氢或一起表示一个键，
R3是1-7C烷基，
R4是1-4C烷基，
R5是1-4C烷基。
优选的式1化合物为这样一些化合物及其盐，其中
R1是甲基，
R2a和R2b都是氢或一起表示一个键，
R3是叔丁基，
R4是甲基，和
R5是甲基。
本发明化合物可以例如按照下面的反应示意流程来制备。示意流程
在下面的示意流程中，式1化合物的制备用实例方式描述，式中R2a和R2b都是氢(相当于式1a化合物)。
初始的式(2)化合物叙述于WO 01/72748。式(3)的硅醚也是本发明的主题，它可按照专家已知的方法来制备，例如，在碱性条件下，使苯基异丝氨酸乙酯与叔丁基二甲基氯化硅反应。(2)与(3)的反应优选在合适的催化剂存在下进行，例如，对甲苯磺酸，并且同时进行除水。最初形成中间体亚胺，然后进行环闭合，该反应通过使用强碱来进行，例如叔丁酸钾，叔丁酸锂，双(三甲基硅基)氨基钠，或优选的二异丙基氨基锂。
为了制备如下的式1化合物，其中R2a和R2b一起表示一个键(相当于式1b化合物)，
将式1a化合物用适当的试剂脱氢(氧化)，例如使用二氧化锰，1，3-二氯-5，5-二甲基乙内酰脲或2，3-二氯-5，6-二氰基-p-苯并醌(DDQ)。
例如在国际专利申请WO 98/42707中的示意流程8中作为中间体列出的8-羟基-7-氧代-7，8，9，10-四氢咪唑并[1，2-h][1，7]二氮杂萘可从化合物1b通过例如用盐酸水解制得。因此，本发明还涉及式1b化合物通过其水解在制备式4化合物中的应用。
下面的实施例用来更加详细地说明本发明，并不限制本发明。类似地，其他的式1化合物(此处没有明确地叙述其制备方法)可以通过类似方法或者用本领域技术人员本身熟悉的方法、用常规技术来制得。缩写min表示分钟，h表示小时。
实施例
1.苯基异丝氨酸乙酯的叔丁基-二甲基-硅醚
将1323克(4.06摩尔)(R，R)-苯基异丝氨酸乙酯溶解于6.6升二氯甲烷中。向此溶液中加入397.4克咪唑和724克叔丁基二甲基氯化硅。将混合物在室温搅拌16小时。然后依次用6升和4升水洗涤该反应混合物。得到的清亮二氯甲烷层用硫酸钠干燥，过滤并减压浓缩。得到的1509克标题化合物不需纯化可直接用于实施例2。
2.7-(叔丁基-二甲基硅烷基氧)-2，3-二甲基-8-苯基-5，7，8，9-四氢-4H-1，3a，9-三氮杂环戊二烯并[a]萘-6-酮
往溶解在10.5升甲苯中的实施例1得到的1509克苯基异丝氨酸乙酯的叔丁基-二甲基硅醚中加入14克对甲苯磺酸一水合物和736克2，3-二甲基-6，7-二氢-5-H-咪唑并[1，2-a]吡啶-8-酮。将混合物搅拌并在回流状态下煮沸，直到在所用的Dean-Stark集水器中收集到80毫升水为止。将混合物冷冻至-15℃，加入6升四氢呋喃。用1小时往此溶液中滴加6升2M的二异丙基氨基锂(在四氢呋喃/正庚烷中的溶液)。将该混合物在没有外部冷却的条件下搅拌30分钟(温度升至-5℃)，然后用7升氯化铵水溶液使反应终止。分出两层。有机层用硫酸钠干燥并过滤。真空除去溶剂后，分离出1811克粗的7-(叔丁基-二甲基-硅烷基氧)-2，3-二甲基-8-苯基-5，7，8，9-四氢-4H-1，3a，9-三氮杂-环戊二烯并[a]萘-6-酮。将该物质溶解于3.9升沸腾的甲醇中，并搅拌冷冻至-5℃。收集形成的沉淀，并用1.75升冷甲醇洗涤。干燥后得到558克标题化合物。将母液浓缩至1.5升，并在-5℃搅拌几小时。收集沉淀，用0.25升甲醇洗涤。分离出另一部分96.5克标题化合物。总收率是654.5克(38.5％)。
3.7-(叔丁基-二甲基-硅烷氧基)-2，3-二甲基-8-苯基-8，9-二氢-7H-1，3a，9-三氮杂环戊二烯并[a]萘-6-酮
将558克(1.32摩尔)7-(叔丁基-二甲基-硅烷氧基)-2，3-二甲基-8-苯基-5，7，8，9-四氢-4H-1，3a，9三氮杂环戊二烯并[a]萘-6-酮溶于2.6升THF和5.36升甲苯中。将混合物搅拌并在5℃的冰/水浴中冷冻。用1小时时间分批加入376克(1.66摩尔)DDQ。在15℃继续搅拌另外2小时。氧化完全以后(用HPLC检查)，反应混合物用2.066升2M氢氧化钠水溶液骤冷。将得到的悬浮液过滤，滤饼用1升甲苯洗涤。将呈两层体系的滤液分开，有机层用2升10％氯化钠水溶液洗。用硫酸钠干燥后，有机层经过滤并减压浓缩。粗产品用0.5升甲醇处理，并再次真空浓缩。将536克标题化合物粗品溶于700毫升甲醇并冷冻至-15℃。收集形成的沉淀，用100毫升冷(-15℃)甲醇洗涤并干燥。得到342克标题化合物黄色固体。
4.7-羟基-2，3-二甲基-8-苯基-8，9-二氢-7H-1，3a，9-三氮杂环戊二烯并[a]萘-6-酮
将386.5克(0.916摩尔)7-(叔丁基-二甲基-硅烷氧基)-2，3-二甲基-8-苯基-8，9-二氢-7H-1，3a，9-三氮杂-环戊二烯并[a]萘-6-酮悬浮于1.4升甲醇中并在冰/水浴上冷却至10℃。然后加入0.734升30％HCl水溶液。悬浮液变成清澈的，几秒钟之后形成新的沉淀。将得到的悬浮液搅拌2小时。加入1.1升25％氨水后，将此碱性悬浮液(pH＝9.6)搅拌1小时。收集形成的固体并用1.1升水洗涤，然后干燥。为了除去剩余的硅基原料，该固体用1升乙醚洗涤并再次干燥。得到273.5克标题化合物。
Claims (8)
1.式1化合物及其盐，
其中R1是氢、甲基或羟甲基，
R2a和R2b都是氢或一起表示一个键，
R3是1-7C烷基，
R4是1-7C烷基，和
R5是1-7C烷基。
2.权利要求1的式1化合物及其盐，其中
R1是甲基，
R2a和R2b都是氢或一起表示一个键，
R3是1-7C烷基，
R4是1-4C烷基，和
R5是1-4C烷基。
3.权利要求1的式1化合物及其盐，其中
R1是甲基，
R2a和R2b都是氢或一起表示一个键，
R3是叔丁基，
R4是甲基，和
R5是甲基。
4.权利要求1的式1化合物及其盐，其中
R2a和R2b都是氢，其可用式1a表征，
式中R1是氢，甲基或羟甲基，
R3是1-7C烷基，
R4是1-7C烷基，和
R5是1-7C烷基。
5.权利要求1的式1化合物及其盐，其中
R2a和R2b一起表示一个键，其可用式1b表征，
式中R1是氢，甲基或羟甲基，
R3是1-7C烷基，
R4是1-7C烷基，和
R5是1-7C烷基。
6.制备权利要求4中式1a化合物的方法，
包括使式2化合物与式3化合物反应；式2中的R1具有权利要求4中给出的定义，式3中的R3、R4和R5具有权利要求4中给出的定义，并且使得到的亚胺中间体经过环闭合反应。
7.式3化合物，
其中R3是1-7C烷基，
R4是1-7C烷基，和
R5是1-7C烷基。
8.权利要求5的式1b化合物通过将其水解用于制备式4化合物，
其中R1是氢，甲基或羟甲基。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02028672 | 2002-12-20 | ||
| EP02028672.0 | 2002-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1726031A true CN1726031A (zh) | 2006-01-25 |
Family
ID=32668731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA200380105889XA Pending CN1726031A (zh) | 2002-12-20 | 2003-12-18 | 8－三烷基硅氧基－2－甲基－9－苯基－7－氧代－7,8,9,10－四氢咪唑并[1,2－h][1,7]二氮杂萘 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20060041134A1 (zh) |
| EP (1) | EP1585516A2 (zh) |
| JP (1) | JP2006515848A (zh) |
| KR (1) | KR20050088176A (zh) |
| CN (1) | CN1726031A (zh) |
| AU (1) | AU2003293940A1 (zh) |
| BR (1) | BR0316752A (zh) |
| CA (1) | CA2509882A1 (zh) |
| EA (1) | EA010107B1 (zh) |
| HR (1) | HRP20050632A2 (zh) |
| MX (1) | MXPA05006349A (zh) |
| NO (1) | NO20053271L (zh) |
| PL (1) | PL375933A1 (zh) |
| RS (1) | RS20050449A (zh) |
| WO (1) | WO2004056362A2 (zh) |
| ZA (1) | ZA200504045B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006008170A1 (en) * | 2004-07-23 | 2006-01-26 | Dsm Ip Assets B.V. | Process for the preparation of (2r, 3r)-2-hydroxy-3-amino-3-aryl-propionamide and (2r, 3r)-2-hydroxy-3-amino-3-aryl-propionic acid alkyl ester |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0001555A3 (en) * | 1997-10-30 | 2001-01-29 | Altana Pharma Ag | Tetrahydro-imidazo-naphthyridine derivatives, pharmaceutical compositions thereof and process for their preparation |
| HUP0102990A3 (en) * | 1998-09-23 | 2002-09-30 | Altana Pharma Ag | Tetrahydroimidazo-naphtyridine derivatives and pharmaceutical compositions thereof |
| BR0109542A (pt) * | 2000-03-29 | 2003-06-10 | Altana Pharma Ag | Derivados de imidazopirina alquilados |
| ATE311389T1 (de) * | 2000-03-29 | 2005-12-15 | Altana Pharma Ag | Wirkstoffvorläufer von imidazopyridin-derivaten |
| MXPA02009549A (es) * | 2000-03-29 | 2004-05-14 | Altana Pharma Ag | Imidazopiridinas triciclicas. |
| AU783550B2 (en) * | 2000-03-29 | 2005-11-10 | Altana Pharma Ag | Imidazopyridin-8-ones |
| EA008151B1 (ru) * | 2000-10-25 | 2007-04-27 | Алтана Фарма Аг | Полизамещенные имидазопиридины в качестве ингибиторов желудочной секреции |
| TWI295575B (en) * | 2002-04-24 | 2008-04-11 | Altana Pharma Ag | Nitrosated imidazopyridines |
-
2003
- 2003-12-18 WO PCT/EP2003/014554 patent/WO2004056362A2/en active Application Filing
- 2003-12-18 PL PL03375933A patent/PL375933A1/xx unknown
- 2003-12-18 KR KR1020057010884A patent/KR20050088176A/ko not_active Application Discontinuation
- 2003-12-18 JP JP2004561364A patent/JP2006515848A/ja not_active Withdrawn
- 2003-12-18 RS YUP-2005/0449A patent/RS20050449A/sr unknown
- 2003-12-18 EA EA200500903A patent/EA010107B1/ru not_active IP Right Cessation
- 2003-12-18 AU AU2003293940A patent/AU2003293940A1/en not_active Abandoned
- 2003-12-18 MX MXPA05006349A patent/MXPA05006349A/es not_active Application Discontinuation
- 2003-12-18 EP EP03789344A patent/EP1585516A2/en not_active Withdrawn
- 2003-12-18 US US10/538,933 patent/US20060041134A1/en not_active Abandoned
- 2003-12-18 BR BR0316752-6A patent/BR0316752A/pt not_active IP Right Cessation
- 2003-12-18 CN CNA200380105889XA patent/CN1726031A/zh active Pending
- 2003-12-18 CA CA002509882A patent/CA2509882A1/en not_active Abandoned
-
2005
- 2005-05-19 ZA ZA200504045A patent/ZA200504045B/en unknown
- 2005-07-04 NO NO20053271A patent/NO20053271L/no not_active Application Discontinuation
- 2005-07-11 HR HR20050632A patent/HRP20050632A2/hr not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004056362A3 (en) | 2004-09-02 |
| MXPA05006349A (es) | 2005-08-26 |
| AU2003293940A1 (en) | 2004-07-14 |
| BR0316752A (pt) | 2005-10-25 |
| PL375933A1 (en) | 2005-12-12 |
| HRP20050632A2 (hr) | 2006-04-30 |
| EP1585516A2 (en) | 2005-10-19 |
| ZA200504045B (en) | 2006-07-26 |
| NO20053271L (no) | 2005-07-04 |
| US20060041134A1 (en) | 2006-02-23 |
| JP2006515848A (ja) | 2006-06-08 |
| WO2004056362A2 (en) | 2004-07-08 |
| EA010107B1 (ru) | 2008-06-30 |
| CA2509882A1 (en) | 2004-07-08 |
| EA200500903A1 (ru) | 2005-12-29 |
| KR20050088176A (ko) | 2005-09-02 |
| RS20050449A (en) | 2007-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108164550A (zh) | 一种他唑巴坦酸、他唑巴坦二苯甲酯制备工艺与应用 | |
| WO2008138228A1 (fr) | Procédé de préparation de sodium de cilastatine | |
| WO2012126148A1 (zh) | 一种纯化盐酸头孢替安的新制法 | |
| CN102816172A (zh) | 一种头孢孟多酯钠的制备工艺 | |
| CN102617601A (zh) | 一种头孢地尼的制备方法 | |
| CA2471730C (en) | Process for preparing and purifying 1,7'-dimethyl-2'-propyl-2,5'-bi-1h-benzimidazole | |
| CN1726031A (zh) | 8－三烷基硅氧基－2－甲基－9－苯基－7－氧代－7,8,9,10－四氢咪唑并[1,2－h][1,7]二氮杂萘 | |
| CN1423558A (zh) | 新的制备托拉塞米中间体的方法 | |
| US6770762B2 (en) | Process for preparing and purifying 1,7′-dimethyl-2′-propyl-2,5′-bi-1H-benzimidazole | |
| CN1431211A (zh) | 头孢硫脒胺盐、制备方法及应用 | |
| CZ282048B6 (cs) | Způsob přípravy čistého oxytetracyklinu a meziprodukt pro tuto přípravu | |
| US4610822A (en) | Process for preparing 6-[D(-)-α-(4-C1 -C4)-alkyl-2,3-dioxo-1-piperazinocarbonylamino)phenylacetamido]penicillanic acids | |
| CN112457327A (zh) | 一种d-生物素的制备方法 | |
| KR810001135B1 (ko) | 탈암피실린 염산염의 제조방법 | |
| CN113563181A (zh) | 吉非罗齐杂质的去除方法 | |
| JPS6368561A (ja) | 〔１ｈ〕−イソインドリン−１−オン−３−カルボン酸の改良された製造方法 | |
| JPS5939896A (ja) | ５−メチル−７−ジエチルアミノ−ｓ−トリアゾロ〔１，５−ａ〕ピリミジンの精製法 | |
| CN1764665A (zh) | 咪唑并吡啶－8－酮的生产方法 | |
| KR100230642B1 (ko) | 페니실란산 1,1-디옥시드 및 그 염의 제조방법 | |
| KR850000611B1 (ko) | 6-[d(-)-알파-(4-c₁~c₄)알킬-2,3-디옥소-1-피페라지노 카르보닐아미노)페닐아세트아미도] 페니실란산 제조방법 | |
| JPH06128260A (ja) | 新規なイミダゾピロロキノリン化合物 | |
| JP2001002656A (ja) | ２−アルキル−４−クロロ−５−ヒドロキシメチルイミダゾール誘導体の製造法 | |
| JP2002531571A (ja) | ペニシラン酸スルホキシドエステルの製造方法 | |
| JPH0570460A (ja) | 新規なピロロキノリン化合物 | |
| JPS6299363A (ja) | フエニルバルビツ−ル酸類 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1087339 Country of ref document: HK |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1087339 Country of ref document: HK |